BIO RAD LABORATORIES INC Form 8-K March 29, 2011

# **UNITED STATES**

### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 8-K

# **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report: March 23, 2011

(Date of earliest event reported)

#### **BIO-RAD LABORATORIES, INC.**

(Exact name of registrant as specified in its charter)

Edgar Filing: BIO RAD LABORATORIES INC - Form 8-K

**Commission File Number: 1-7928** 

Delaware (State or other jurisdiction of

incorporation or organization)

94-1381833 (I.R.S. Employer

**Identification No.**)

#### 1000 Alfred Nobel Dr.

#### Hercules, California 94547

(Address of principal executive offices, including zip code)

(510) 724-7000

(Registrant s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

" Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

### Edgar Filing: BIO RAD LABORATORIES INC - Form 8-K

- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

# ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Effective March 23, 2011, James J. Bennett retired from the Board of Directors of Bio-Rad Laboratories, Inc.

(Bio-Rad or the Company), a position he held since 1977. Mr. Bennett served Bio-Rad in several key operating positions during his 33-year association with the Company.

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### **BIO-RAD LABORATORIES, INC.**

Date: March 29, 2011

By:

/s/ Christine A. Tsingos

Christine A. Tsingos Vice President, Chief Financial Officer

TD>Exhibit 4.1 Supplemental Indenture (including the form of Notes), dated as of November 16, 2011, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee.Exhibit 5.1 Opinion of Debevoise & Plimpton LLPExhibit 23.1 Consent of Debevoise & Plimpton LLP (contained in Exhibit 5.1).

2

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTERNATIONAL PAPER COMPANY

By: /s/ Sharon R. Ryan Name: Sharon R. Ryan Title: Senior Vice President, General Counsel and Corporate Secretary

Date: November 16, 2011

3

### EXHIBIT INDEX

Exhibit Number	Description
Exhibit 1.1	Underwriting Agreement, dated November 8, 2011, by and among the Company and BNP Paribas Securities Corp., Deutsche Bank Securities Inc., HSBC Securities (USA) Inc., RBS Securities Inc. and UBS Securities LLC, as representatives of the underwriters named in Schedule A thereto.
Exhibit 4.1	Supplemental Indenture (including the form of Notes), dated as of November 16, 2011, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee.
Exhibit 5.1	Opinion of Debevoise & Plimpton LLP.
Exhibit 23.1	Consent of Debevoise & Plimpton LLP (contained in Exhibit 5.1).

4